Search | Clinical Trials Finder

Conditions: Retinal Vein Occlusion, Macular Edema
Interventions: Intravitreal injection of bevacizumab, Intravitreal injection of ranibizumab (0.5 mg per dose); Drug
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Diabetic Macular Edema
Interventions: LKA651, Lucentis; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more

Conditions: Retinal Vein Occlusion, Diabetic Macular Edema, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion
Interventions: Aflibercept; Drug
Lead sponsor: Justis Ehlers; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Retinal Vein Occlusion
Interventions: Aflibercept; Drug
Lead sponsor: Tennessee Retina; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Retinal Vein Occlusions
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Deep Vein Thrombosis
Interventions: Mayo Dopplex ABIlity, Intermittent Pneumatic Compression (IPC); Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Veno-occlusive Disease
Interventions: defibrotide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 18 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 9
States / cities: Duarte, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Veno-occlusive Disease
Interventions: Defibrotide, Best Supportive Care; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Month and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 37
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more

Conditions: Macular Edema
Interventions: Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone; Device · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: Not listed
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Retinal Vein Occlusion
Interventions: Aflibercept Ophthalmic; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy
Interventions: Miconazole, L-NMMA, Bradykinin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatic Veno-occlusive Disease
Interventions: Defibrotide; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Central Retinal Vein Occlusion
Interventions: Autologous Bone Marrow CD34+ Stem Cells, Sham Therapy; Biological
Lead sponsor: The Emmes Company, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Ischemia, Retinal Vein Occlusion, Pathologic Processes, Retinal Diseases, Eye Diseases
Interventions: ranibizumab; Drug
Lead sponsor: David M. Brown, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Iliac Venous Compression
Interventions: Not listed
Lead sponsor: Volcano Corporation; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 11
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bridgeport, Connecticut + 8 more

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Interventions: Faricimab, Port Delivery System with Ranibizumab; Drug · Combination Product
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 18
States / cities: Phoenix, Arizona • Pasadena, California • Sacramento, California + 15 more

Conditions: Macular Edema, Central Retinal Vein Occlusion
Interventions: Ozurdex, Avastin; Drug
Lead sponsor: Long Island Vitreoretinal Consultants; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 4
States / cities: Toms River, New Jersey • Great Neck, New York • Hauppauge, New York + 1 more

Conditions: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: VEGF Trap-Eye 2.0mg, Sham; Biological · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more

Conditions: Sinusoidal Obstruction Syndrome
Interventions: Serial Blood Draws; Other
Lead sponsor: Indiana University; Other
Eligibility: Up to 25 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • Ann Arbor, Michigan + 1 more

Conditions: Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: bevacizumab; Biological
Lead sponsor: Outlook Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Springfield, Illinois • Hagerstown, Maryland • Chambersburg, Pennsylvania

Conditions: Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions: Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug; Procedure · Drug
Lead sponsor: Retina Vitreous Associates of Florida; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Clearwater, Florida

Conditions: Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
Interventions: GORE® VIAFORT Vascular Stent; Device
Lead sponsor: W.L.Gore & Associates; Industry
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 8
States / cities: Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Search by objective public record fields.

Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

OCT in Retinal Vein Occlusions

Non-invasive Venous Air Plethysmography Assessment of Venous Hemodynamics in Patients Suspected Deep Venous Obstruction Used in Conjunction With Intermittent Pneumatic Compression.

Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation

Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment

Effects of Miconazole on Blood Flow

Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver

Treatment of Central Retinal Vein Occlusion Using Stem Cells Study

Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

Venogram vs. Intravascular Ultrasound (IVUS) for Diagnosing Iliac Vein Obstruction

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study

A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)